Phase IIa Study of PLX2853 in Gynecologic Cancers With Known ARID1A Mutation and Phase Ib/IIa Study of PLX2853/Carboplatin in Platinum-Resistant Epithelial Ovarian Cancer.
Linda R DuskaDmitriy ZamarinErika Paige HamiltonAmit M OzaGini F FlemingAlexander I SpiraOladapo O YekuDebra L RichardsonJackie WallingKerry InokuchiBernice MatusowGideon BollagElizabeth M SwisherPublished in: JCO precision oncology (2023)
-mutated gynecologic malignancies, possibly in combination with agents targeting potential feedback mechanisms such as the PI3K pathway.